Immediate Impact
21 standout
Citing Papers
Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents
2024 Standout
New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
Works of Waldo Jiménez being referenced
Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.
2021
Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Waldo Jiménez | 125 | 94 | 119 | 19 | 244 | |
| A Nordin | 129 | 100 | 132 | 15 | 290 | |
| G. M. Moralez | 60 | 44 | 82 | 14 | 213 | |
| Ariella Jakobson‐Setton | 87 | 56 | 39 | 20 | 206 | |
| Eva Myriokefalitaki | 69 | 148 | 77 | 17 | 282 | |
| Frederico Soares Falcetta | 76 | 81 | 79 | 18 | 291 | |
| J.L. McKelvey | 80 | 63 | 77 | 12 | 210 | |
| C. Dalrymple | 126 | 108 | 129 | 19 | 275 | |
| Lukáš Dostálek | 182 | 74 | 118 | 24 | 241 | |
| Julie Sandstad | 102 | 102 | 52 | 14 | 263 | |
| Rafli van de Laar | 96 | 107 | 62 | 15 | 261 |
All Works
Loading papers...